dsm-firmenich Completes Strategic Pivot with Animal Nutrition Exit
Event summary
- dsm-firmenich finalized the divestment of its Animal Nutrition & Health business to CVC Capital Partners for €2.2 billion, including a €0.5 billion earn-out.
- The company reported €9.03 billion in sales for 2025, with a 3% organic sales growth and a stable adjusted EBITDA margin of 19.6%.
- dsm-firmenich launched a €500 million share repurchase program and maintained a €2.50 dividend per share.
- The company achieved sustainability milestones, including EcoVadis Platinum and CDP double A ratings for Climate & Water.
The big picture
dsm-firmenich's divestment of Animal Nutrition & Health marks the culmination of its strategic shift towards a consumer-focused portfolio in nutrition, health, and beauty. The move aligns with broader industry trends of specialization and portfolio optimization, positioning the company to capitalize on innovation-driven growth in its core segments. With a strong financial performance and sustainability achievements, dsm-firmenich is poised to deliver on its mid-term ambitions, though execution risks and market dynamics remain critical factors.
What we're watching
- Execution Risk
- How dsm-firmenich will integrate the remaining €115 million in revenue synergies by 2027.
- Market Positioning
- Whether the focus on Perfumery & Beauty, Taste, Texture & Health, and Health, Nutrition & Care will drive mid-term growth.
- Financial Discipline
- The pace at which the company will achieve its mid-term financial ambitions, including a 5-7% organic sales growth and a 22-23% adjusted EBITDA margin.
Related topics